Pfizer & Alex Therapeutics Launch Strategic Commercial Partnership To Pilot Digital Therapeutic to Treat Nicotine Addiction In Germany

Alex Therapeutics AB, a Swedish digital therapeutics company, and pharmaceutical company Pfizer, launched a strategic commercial partnership. The partnership will initially focus on Germany to pilot a digital therapy to treat nicotine addiction via a smartphone program called Elia using the Alex DTx Platform.

The medical device Elia was developed by Alex Therapeutics and adapted to the requirements of the German health care system together with Pfizer Germany. Pfizer is currently conducting an extensive clinical trial in Germany to further validate the medical benefits of the solution. After the clinical trial ends, the market rollout will begin.

The Alex DTx . . .